Web14 apr. 2024 · Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%. The most common adverse reactions (incidence ≥20%) in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, … WebThe objective of this study was to describe characteristics and treatment patterns in patients with R/R DLBCL post-CAR-T approval. Methods Adult patients with R/R DLBCL who initiated third-line treatment or later (3 L+) since 18 October 2024 were identified using administrative claims from IQVIA PharMetrics Plus (1 January 2014-31 March 2024).
Newer Agents on the Horizon for Refractory or Relapsed DLBCL
Web5 apr. 2024 · Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. … WebMatching-adjusted indirect comparison (MAIC) was used to evaluate the efficacy of Lonca versus CIT-era treatment in R/R DLBCL. The analysis used individual patient data from the phase II LOTIS-2 trial of Lonca (NCT03589469) and pooled aggregated data from 2 extension studies of the CORAL trial for CIT. irobot roomba 960 specifications
Pre-phase strategy to mitigate first cycle effect in diffuse large B ...
Web46 minuten geleden · Reviewing Key Efficacy and Safety Data for Tafasitamab Plus Lenalidomide in DLBCL. Apr 14, 2024. Targeted Oncology Staff. During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with … Websient antitumor activity in R/R DLBCL,4 with the exception of patients with HIV-related lymphoma, that may benefit of a long-term disease control.5 About 60 per cent of patients treated with axicabtagene ciloleucel for a relapsing or refractory diffuse large B cell lym - phoma (R/R DLBCL) do not achieve a persistent response.6 WebDiffuse Large B-Cell Lymphoma or DLBCL is the most commonly diagnosed subtype of Non-Hodgkin Lymphoma. Dr. John Kuruvilla will discuss diagnosis and approach... irobot roomba 780 vacuum cleaning robot